Tags

Type your tag names separated by a space and hit enter

Small-molecule antiviral agents in ongoing clinical trials for COVID-19.
Curr Drug Targets. 2021 Feb 14 [Online ahead of print]CD

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 and has rapidly spread globally. As the confirmed number of cases has reached to 83 million worldwide, the potential severity and the deadly complications of the disease requires urgent development of effective drugs for prevention and treatment. No proven effective treatment for this virus currently exists. Most of the antiviral discovery efforts are focused on the repurposing of approved or clinical stage drugs. This review highlights the small-molecule repurposed antiviral agents that are currently under investigation in clinical trials for COVID19. These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed.

Authors+Show Affiliations

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, 34116. Turkey.Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, 34116. Turkey.Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, 34116. Turkey.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33588727

Citation

Apaydın, Çağla Begüm, et al. "Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19." Current Drug Targets, 2021.
Apaydın ÇB, Çınar G, Cihan-Üstündağ G. Small-molecule antiviral agents in ongoing clinical trials for COVID-19. Curr Drug Targets. 2021.
Apaydın, Ç. B., Çınar, G., & Cihan-Üstündağ, G. (2021). Small-molecule antiviral agents in ongoing clinical trials for COVID-19. Current Drug Targets. https://doi.org/10.2174/1389450122666210215112150
Apaydın ÇB, Çınar G, Cihan-Üstündağ G. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19. Curr Drug Targets. 2021 Feb 14; PubMed PMID: 33588727.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Small-molecule antiviral agents in ongoing clinical trials for COVID-19. AU - Apaydın,Çağla Begüm, AU - Çınar,Gözde, AU - Cihan-Üstündağ,Gökçe, Y1 - 2021/02/14/ PY - 2020/11/24/received PY - 2021/01/07/revised PY - 2021/01/11/accepted PY - 2021/2/16/entrez PY - 2021/2/17/pubmed PY - 2021/2/17/medline KW - Antiviral therapy KW - COVID-19 KW - Clinical trial KW - Mechanism of action KW - Preclinical study KW - SARS-CoV-2 JF - Current drug targets JO - Curr Drug Targets N2 - The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 and has rapidly spread globally. As the confirmed number of cases has reached to 83 million worldwide, the potential severity and the deadly complications of the disease requires urgent development of effective drugs for prevention and treatment. No proven effective treatment for this virus currently exists. Most of the antiviral discovery efforts are focused on the repurposing of approved or clinical stage drugs. This review highlights the small-molecule repurposed antiviral agents that are currently under investigation in clinical trials for COVID19. These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed. SN - 1873-5592 UR - https://www.unboundmedicine.com/medline/citation/33588727/Small_molecule_antiviral_agents_in_ongoing_clinical_trials_for_COVID_19_ L2 - https://www.eurekaselect.com/191400/article DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.